Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis.
| dc.contributor.author | Lau, Sin C | |
| dc.contributor.author | Rosa, Daniela D | |
| dc.contributor.author | Jayson, Gordon C | |
| dc.date.accessioned | 2009-07-24T15:40:45Z | |
| dc.date.available | 2009-07-24T15:40:45Z | |
| dc.date.issued | 2005-10 | |
| dc.identifier.citation | Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. 2005, 7 (5):493-501 Curr. Opin. Mol. Ther. | en |
| dc.identifier.issn | 1464-8431 | |
| dc.identifier.pmid | 16248285 | |
| dc.identifier.uri | http://hdl.handle.net/10541/75665 | |
| dc.description.abstract | sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer. | |
| dc.language.iso | en | en |
| dc.subject | Cancer | en |
| dc.subject.mesh | Angiogenesis Inhibitors | |
| dc.subject.mesh | Animals | |
| dc.subject.mesh | Clinical Trials, Phase I as Topic | |
| dc.subject.mesh | Drug Evaluation, Preclinical | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Mice | |
| dc.subject.mesh | Neoplasms | |
| dc.subject.mesh | Vascular Endothelial Growth Factor A | |
| dc.subject.mesh | Vascular Endothelial Growth Factor Receptor-1 | |
| dc.subject.mesh | Vascular Endothelial Growth Factor Receptor-2 | |
| dc.title | Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. | en |
| dc.type | Article | en |
| dc.contributor.department | Cancer Research UK, Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK. | en |
| dc.identifier.journal | Current Opinion in Molecular Therapeutics | en |
| html.description.abstract | sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer. |